Výsledky vyhledávání - "Colin Rothwell"

Akademický článek

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Publikováno v: PLoS ONE, Vol 14, Iss 5, p e0216934 (2019)

BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized

Externí odkaz: https://doaj.org/article/a30bb6a9379947f68513ccbaae968fe8

Zobrazit plný text záznamu

Plný text ve formátu HTML

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Publikováno v: Journal of Clinical Oncology

PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77dd9de4415592c0cc44b7e637139feb
https://doi.org/10.1200/jco.18.01731

Zobrazit plný text záznamu

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer

Autor: Daniel J. George, Monika Anand, David M. Nanus, Gabor Kemeny, Daniel H. Hovelson, Jun Luo, Andrew J. Armstrong, Jason A. Somarelli, Santosh Gupta, Emmanuel S. Antonarakis, Ryan Dittamore, Susan Halabi, Scott A. Tomlins, Simon G. Gregory, Colin Rothwell, Wen-Chi Foo

Publikováno v: Genes, chromosomescancerREFERENCES. 59(4)

Circulating tumor cell (CTC) and cell-free (cf) DNA-based genomic alterations are increasingly being used for clinical decision-making in oncology. However, the concordance and discordance between paired CTC and cfDNA genomic profiles remain largely

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb9422efc1152e8c843121f7c87796b
https://pubmed.ncbi.nlm.nih.gov/31705765

Zobrazit plný text záznamu

Fast Protection-Domain Crossing in the CHERI Capability-System Architecture

Autor: Jonathan Anderson, Peter G. Neumann, Robert Norton, Stacey Son, Brooks Davis, Jonathan Woodruff, Alexandre Joannou, Nirav H. Dave, Khilan Gudka, Ed Maste, Steven J. Murdoch, A. Theodore Markettos, Michael Roe, Simon W. Moore, Colin Rothwell, Munraj Vadera, Ben Laurie, Robert N. M. Watson, David Chisnall

Publikováno v: IEEE Micro. 36:38-49

Capability Hardware Enhanced RISC Instructions (CHERI) supplement the conventional memory management unit (MMU) with instruction-set architecture (ISA) extensions that implement a capability system model in the address space. CHERI can also underpin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae4b85c6e4842aeeda73fa15322bae7
https://doi.org/10.1109/mm.2016.84

Zobrazit plný text záznamu

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223

Autor: Andrew J. Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Katie Ware, Jason Somarelli, Kris Wood, Thomas Ribar, Drew Gerber, Monika Anand, Susan Halabi, Simon Gregory, Daniel J. George

Publikováno v: Journal of Clinical Oncology. 36:5029-5029

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9959ca30616207be6ef253f46368bbe5
https://doi.org/10.1200/jco.2018.36.15_suppl.5029

Zobrazit plný text záznamu

The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)

Publikováno v: Journal of Clinical Oncology. 36:5004-5004

5004Background: It is unclear if CTC AR-V7 detection is a valid predictive biomarker of clinical efficacy in men with mCRPC receiving A/E or just an indicator of aggressive disease and high tumor b...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3689c6af2236b0dcc758bab1b4d29d08
https://doi.org/10.1200/jco.2018.36.15_suppl.5004

Zobrazit plný text záznamu

Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC)

Autor: Santosh Gupta, Daniel J. George, Gabor Kemeny, Chia Jen Liu, Scott A. Tomlins, Simon G. Gregory, Monika Anand, Daniel H. Hovelson, Andrew J. Armstrong, Paraskevi Giannakakou, Colin Rothwell, David M. Nanus

Publikováno v: Journal of Clinical Oncology. 36:5065-5065

5065Background: CTC and ctDNA-based, actionable genomic alterations are being increasingly utilized for precision oncology therapies. However, the concordance of genomic alterations in CTC DNA vs. ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5aa65b98e669d6f4544ed4f78af7b189
https://doi.org/10.1200/jco.2018.36.15_suppl.5065

Zobrazit plný text záznamu

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223

Publikováno v: Journal of Clinical Oncology. 36:160-160

160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial plasticity leading to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55c8631e7f0d7ca4d0666acd5aa2df29
https://doi.org/10.1200/jco.2018.36.6_suppl.160

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání